Ponaxen Ponatinib 15 mg Tablet

Ponaxen Ponatinib 15 mg Tablet contains ponatinib, a third-generation tyrosine kinase inhibitor (TKI) indicated for the treatment of certain types of blood cancers, including chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL). It is primarily prescribed for patients who are resistant to or intolerant of prior tyrosine kinase inhibitor therapies or who have specific genetic mutations, such as the T315I mutation. Ponatinib works by blocking abnormal BCR-ABL tyrosine kinase activity, thereby slowing or stopping the growth of leukaemia cells.

Ponaxen Ponatinib 15 mg Tablet helps control disease progression by targeting cancer cells while minimising damage to healthy cells. It is used across different phases of CML, including chronic, accelerated, and blast phases, as determined by a haematologist or oncologist. Regular monitoring during treatment is essential to evaluate therapeutic response and manage potential side effects.

This medicine should be taken exactly as prescribed by a healthcare professional. Consistent treatment, along with routine blood tests and clinical follow-up, helps optimise treatment outcomes. Ponaxen (Ponatinib) 15 mg Tablet is an important targeted therapy that supports long-term disease management and improves treatment options for patients with resistant or mutation-positive leukaemia.

Product Features

• Contains Ponatinib 15 mg, a third-generation tyrosine kinase inhibitor
• Indicated for resistant or intolerant chronic myeloid leukemia (CML)
• Effective against Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
• Targets BCR-ABL kinase, including the T315I mutation
• Supports long-term management of specific leukemia types under specialist supervision

How It Helps

• Blocks abnormal BCR-ABL tyrosine kinase activity
• Slows the growth and spread of leukemia cells
• Helps manage treatment-resistant CML and Ph+ ALL
• Supports improved disease control with targeted therapy